Table 1. Patient Characteristics.
| Patient Characteristics | Derivation (MGH) | Validation (BWH) | Differences | ||
|---|---|---|---|---|---|
| n | % of Total | N | % of Total | Chi Square (p) | |
| Total | 712 | 100.0 | 362 | 100.0 | - |
| Male | 558 | 78.4 | 222 | 61.3 | <0.0001 |
| Age >40 years | 476 | 66.9 | 273 | 75.4 | 0.004 |
| White, non-Hispanic | 416 | 58.4 | 108 | 29.8 | <0.0001 |
| Sub-optimal Adherence* | 185 | 26.0 | 81 | 22.4 | 0.20 |
| CD4 <100/μL | 29 | 4.1 | 13 | 3.6 | 0.70 |
| Drugs/Alcohol | 229 | 32.2 | 86 | 23.8 | 0.004 |
| Heavily ART experienced | 182 | 25.6 | 108 | 29.8 | 0.14 |
| Missed ≥1 Appointment | 277 | 38.9 | 122 | 33.7 | 0.095 |
| Prior Virologic Failure | 532 | 74.7 | 144 | 39.8 | <0.0001 |
| Psychiatric condition | 309 | 43.4 | 94 | 26.0 | <0.0001 |
| Suppressed <12 months | 306 | 43.0 | 112 | 30.9 | 0.0001 |
Definitions:
“Drugs/Alcohol” - current or past history of drugs or alcohol abuse.
“Missed ≥1 Appointments” in the previous year.
“Heavily ART Experienced”- prior nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors containing regimens prior to the current regimen, or a current enfuvirtide or investigational antiretroviral containing regimen.
*
For the derivation cohort, quantitative measures of adherence were used for 322 (45.2%) patients, qualitative descriptors for 245 (34.5%), and for 145 (20.4%) estimates of adherence were not available in the EHR.